Following identification as a potential biomarker, SEPT9 was evaluated in retrospective trials comparing plasma methylation in people diagnosed with colorectal cancer and healthy controls (Grutzmann et al., 2008; Devos et al., 2009; Warren et al., 2011). Here, SEPTIN9 is linked to colorectal cancer.